Agomelatine for depression: expanding the horizons?

References

• Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391:1357–1366.
   PubMed Web of Science ®Google Scholar
• Parikh SV, Kennedy SH. More data, more answers: picking the optimal antidepressant. Lancet. 2018;391:1333–1334.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Ann Rev Public Health. 2013;34:119–138.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association (APA). Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. Arlington, VA: APA; 2010.
   Google Scholar
• National Institute for Health and Care Excellence (NICE) [webpage on the Internet]. Depression: the treatment and management of depression in adults (update). NICE clinical guideline 90. NICE; 2009 [updated 2014 Feb 6; cited 2018 Aug 24]. Available from: http://www.nice.org.uk/CG90
   Google Scholar
• Short B, Fong J, Galvez V, et al. Side-effects associated with ketamine use in depression: a systematic review. Lancet (Psychiatry). 2018;5:65–78.
   PubMed Web of Science ®Google Scholar
• Millan MJ, Gobert A, Lejeune F, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine-2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharm Exp Ther. 2003;306:954–964.
   PubMed Web of Science ®Google Scholar
• de Bodinat C, Guardiola-Lemaitre B, Mocaer E, et al. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov. 2010;9:628–642.
   PubMed Web of Science ®Google Scholar
• Guardiola-Lemaitre B, de Bodinat C, Delagrange P, et al. Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties. Br J Pharmacol. 2014;171:3604–3619.
   PubMed Web of Science ®Google Scholar
• Srinivasan V, De Berardis D, Shillcutt SD, et al. Role of melatonin in mood disorders and the antidepressant effects of agomelatine. Expert Opin Investig Drugs. 2012;21:1503–1522.
   PubMed Web of Science ®Google Scholar
• Schmelting B, Corbach-Sohle S, Kohlhause S, et al. Agomelatine in the tree shrew model of depression: effects on stress-induced nocturnal hyperthermia and hormonal status. Eur Neuropsychopharmacol. 2014;24:437–447.
   PubMed Web of Science ®Google Scholar
• Norman TR, Cranston I, Irons JA, et al. Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: a comparison to melatonin and to the 5-HT2C antagonist, S32006. Eur J Pharmacol. 2012;674:27–32.
   PubMed Web of Science ®Google Scholar
• Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006;59:1116–1127.
   PubMed Web of Science ®Google Scholar
• Calabrese F, Molteni R, Gabriel C, et al. Modulation of neuroplastic molecules in selected brain regions after chronic administration of the novel antidepressant agomelatine. Psychopharmacology (Berl). 2011;215:267–275.
   PubMed Web of Science ®Google Scholar
• Redman JR, Guardiola-Lemaitre B, Brown M, et al. Dose dependent effects of S-20098, a melatonin agonist, on direction of re-entrainment of rat circadian activity rhythms. Psychopharmacology (Berl). 1995;118:385–390.
   PubMed Web of Science ®Google Scholar
• Armstrong SM, McNulty OM, Guardiola-Lemaitre B, et al. Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS). Pharmacol Biochem Behav. 1993;46:45–49.
   PubMed Web of Science ®Google Scholar
• Quera Salva MA, Vanier B, Laredo J, et al. Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int J Neuropsychopharmacol. 2007;10:691–696.
   PubMed Web of Science ®Google Scholar
• Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry. 2007;68:1723–1732.
   PubMed Web of Science ®Google Scholar
• Kasper S, Hajak G, Wulff K, et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry. 2010;71:109–120.
   PubMed Web of Science ®Google Scholar
• CHMP Assessment Report for Valdoxan. [cited 2018 Aug 27]. Available from: http://ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000915/WC500046226.pdf
   Google Scholar
• Kasper S, Corruble E, Hale A, et al. Antidepressant efficacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head-to-head studies without a placebo control. Int Clin Psychopharmacol. 2013;28:12–19.
   PubMed Web of Science ®Google Scholar
• Singh SP, Singh V, Kar N. Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal. Int J Neuropsychopharmacol. 2011;23:1–12.
   Google Scholar
• Koesters M, Guaiana G, Cipriani A, et al. Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials. Br J Psychiatry. 2013;203:179–187.
   PubMed Web of Science ®Google Scholar
• Taylor D, Sparshatt A, Varma S, et al. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ. 2014;348:g1888.
   PubMed Web of Science ®Google Scholar
• Ambresin G, Gunn J. Does agomelatine have a place in the treatment of depression? Only as an alternative second line therapy for those with severe symptoms. BMJ. 2014;348:g2157.
   PubMedGoogle Scholar
• Montgomery S, Kasper S. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int J Clin Psychopharmacol. 2007;22:283–291.
   PubMed Web of Science ®Google Scholar
• Loo H, Dalery J, Macher JP, et al. Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatoninergic agonist and selective 5HT(2C) receptors antagonist, in the treatment of major depressive disorders. L’Encephale. 2002;28:356–362.
   PubMed Web of Science ®Google Scholar
• Loo H, Hale A, D’haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol. 2002;17:239–247.
   PubMed Web of Science ®Google Scholar
• Stahl SM, Fava M, Trivedi MH, et al. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. J Clin Psychiatry. 2010;71:616–626.
   PubMed Web of Science ®Google Scholar
• Zajecka J, Schatzberg A, Stahl S, et al. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2010;30:135–144.
   PubMed Web of Science ®Google Scholar
• Carney RM, Shelton RC. Agomelatine for the treatment of major depressive disorder. Expert Opin Pharmacother. 2011;12:2411–2419.
   PubMed Web of Science ®Google Scholar
• Hickie IB, Rogers NL. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet. 2011;378(9791):621–631.
   PubMed Web of Science ®Google Scholar
• Fornaro M, Prestia D, Colicchio S, et al. A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Curr Neuropharmacol. 2010;8:287–304.
   PubMed Web of Science ®Google Scholar
• Goodwin GM. Clinical studies on the efficacy of agomelatine on depressive symptoms. CNS Drugs. 2009;23(Suppl 2):35–39.
   PubMedGoogle Scholar
• Kennedy SH, Heun R, Avedisova A, et al. Effect of agomelatine 25–50 mg on functional outcomes in patients with major depressive disorder. J Affect Disord. 2018;238:122–128.
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Avedisova A, Belaïdi C, et al. Sustained efficacy of agomelatine 10 mg, 25 mg, and 25–50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months. Eur Neuropsychopharmacol. 2016;26:378–389.
   PubMed Web of Science ®Google Scholar
• François C, Nielsen R, Danchenko N, et al. The impact of antidepressant treatments on family functioning in adults with major depressive disorder: a post hoc comparison of vortioxetine and agomelatine. Curr Med Res Opin. 2017;33:1057–1066.
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Nielsen RZ, Poulsen LH, et al. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum Psychopharmacol Clin Exp. 2014;29:470–482.
   PubMed Web of Science ®Google Scholar
• Udristoiu T, Dehelean P, Nuss P, et al. Early effect on general interest, and short-term antidepressant efficacy and safety of agomelatine (25–50mg/day) and escitalopram (10–20mg/day) in outpatients with major depressive disorder. A 12-week randomised double-blind comparative study. J Affect Disord. 2016;199:6–12.
   PubMed Web of Science ®Google Scholar
• Komaram RB, Nukala S, Palla J, et al. A comparative study of efficacy and safety of agomelatine and escitalopram in major depressive disorder. J Clin Diagn Res. 2015;9:VC05–VC08.
   PubMed Web of Science ®Google Scholar
• Shu L, Sulaiman AH, Huang YS, et al. Comparable efficacy and safety of 8 weeks treatment with agomelatine 25–50mg or fluoxetine 20–40mg in Asian out-patients with major depressive disorder. Asian J Psychiatr. 2014;8:26–32.
   PubMedGoogle Scholar
• Yu YM, Gao KR, Yu H, et al. Efficacy and safety of agomelatine vs paroxetine hydrochloride in Chinese Han patients with major depressive disorder: a multicentre, double-blind, noninferiority, randomized controlled trial. J Clin Psychopharmacol. 2018;38:226–233.
   PubMed Web of Science ®Google Scholar
• Chen JW, Xie SQ. Agomelatine versus paroxetine in treating depressive and anxiety symptoms in patients with chronic kidney disease. Neuropsychiatr Dis Treat. 2018;14:547–552.
   PubMed Web of Science ®Google Scholar
• Howland RH. A benefit-risk assessment of agomelatine in the treatment of major depression. Drug Saf. 2011;34:709–731.
   PubMed Web of Science ®Google Scholar
• Goodwin GM, Emsley R, Rembry S, et al. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70:1128–1137.
   PubMed Web of Science ®Google Scholar
• Goodwin GM, Boyer P, Emsley R, et al. Is it time to shift to better characterization of patients in trials assessing novel antidepressants? An example of two relapse prevention studies with agomelatine. Int Clin Psychopharmacol. 2013;28:20–28.
   PubMed Web of Science ®Google Scholar
• Luzny J. Agomelatine in elderly – finally a patient friendly antidepressant in psychogeriatry? Actas Esp Psiquiatr. 2012;40:304–307.
   PubMed Web of Science ®Google Scholar
• Goodwin GM, Thomas P, Heun R, et al. Antidepressant effect in older depressed patients: the lessons of two agomelatine trials. Int Clin Psychopharmacol. 2017;32:184–194.
   PubMed Web of Science ®Google Scholar
• Heun R, Ahokas A, Boyer P, et al. The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study. J Clin Psychiatry. 2013;74:587–594.
   PubMed Web of Science ®Google Scholar
• Grunze H, Vieta E, Goodwin GM, et al. The world federation of societies of biological psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry. 2013;14:154–219.
   PubMed Web of Science ®Google Scholar
• Geoffroy PA, Etain B, Franchi JA, et al. Melatonin and melatonin agonists as adjunctive treatments in bipolar disorders. Curr Pharm Des. 2015;21:3352–3358.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Guelfi JD, Perdrizet-Chevallier C. Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disord. 2007;9:628–635.
   PubMed Web of Science ®Google Scholar
• Eppel AB. Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disord. 2008;10:749–750.
   PubMed Web of Science ®Google Scholar
• Fornaro M, McCarthy MJ, De Berardis D, et al. Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study. Neuropsychiatr Dis Treat. 2013;9:243–251.
   PubMed Web of Science ®Google Scholar
• Yatham LN, Vieta E, Goodwin GM, et al. Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: randomised double-blind placebo-controlled trial. Br J Psychiatry. 2016;208:78–86.
   PubMed Web of Science ®Google Scholar
• Thorpe M, Pannell J, Nance M. Agomelatine-associated manic switch in bipolar depression: a case report. Aust N Z J Psychiatry. 2014;48:958–959.
   PubMed Web of Science ®Google Scholar
• Tu KY, Lin PY. Hypomania soon after shifting from paroxetine to agomelatine in a middle-aged woman with depression. Clin Neuropharmacol. 2014;37:82–83.
   PubMed Web of Science ®Google Scholar
• Pjrek E, Winkler D, Konstantinidis A, et al. Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology (Berl). 2007;190:575–579.
   PubMed Web of Science ®Google Scholar
• Sack RL, Lewy AJ, White DM, et al. Morning vs evening light treatment for winter depression. Evidence that the therapeutic effects of light are mediated by circadian phase shifts. Arch Gen Psychiatry. 1990;47:343–351.
   PubMed Web of Science ®Google Scholar
• Di Giannantonio M, Martinotti G. Anhedonia and major depression: the role of agomelatine. Eur Neuropsychopharmacol. 2012;22(Suppl 3):S505–S510.
   PubMedGoogle Scholar
• Di Giannantonio M, Di Iorio G, Guglielmo R, et al. Major depressive disorder, anhedonia and agomelatine: an open-label study. J Biol Regul Homeost Agents. 2011;25:109–114.
   PubMed Web of Science ®Google Scholar
• Gargoloff PD, Corral R, Herbst L, et al. Effectiveness of agomelatine on anhedonia in depressed patients: an outpatient, open-label, real-world study. Hum Psychopharmacol. 2016;31:412–418.
   PubMed Web of Science ®Google Scholar
• Martinotti G, Sepede G, Gambi F, et al. Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study. J Clin Psychopharmacol. 2012;32:487–491.
   PubMed Web of Science ®Google Scholar
• De Berardis D, Fornaro M, Serroni N, et al. Agomelatine treatment of major depressive disorder in Parkinson’s disease: a case series. J Neuropsychiatry Clin Neurosci. 2013;25:343–345.
   PubMed Web of Science ®Google Scholar
• Avila A, Cardona X, Martin-Baranera M, et al. Agomelatine for depression in Parkinson disease: additional effect on sleep and motor dysfunction. J Clin Psychopharmacol. 2015;35:719–723.
   PubMed Web of Science ®Google Scholar
• Chen JJ, Marsh L. Depression in Parkinson’s disease: identification and management. Pharmacotherapy. 2013;33:972–983.
   PubMed Web of Science ®Google Scholar
• Rocha FL, Murad MG, Stumpf BP, et al. Antidepressants for depression in Parkinson’s disease: systematic review and meta-analysis. J Psychopharmacol. 2013;27:417–423.
   PubMed Web of Science ®Google Scholar
• Karaiskos D, Tzavellas E, Ilias I, et al. Agomelatine and sertraline for the treatment of depression in type 2 diabetes mellitus. Int J Clin Pract. 2013;67:257–260.
   PubMed Web of Science ®Google Scholar
• Phillips PJ. HbA1c and monitoring glycaemia. Aust Fam Physician. 2012;41:37–40.
   PubMed Web of Science ®Google Scholar
• Kang R, He Y, Yan Y, et al. Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial. Neuropsychiatr Dis Treat. 2015;11:1307–1311.
   PubMed Web of Science ®Google Scholar
• Che T, Teng X, Huang Q, et al. Agomelatine versus fluoxetine in glycemic control and treating depressive and anxiety symptoms in type 2 diabetes mellitus subjects: a single-blind randomized controlled trial. Neuropsychiatr Dis Treat. 2018;14:1527–1533.
   PubMed Web of Science ®Google Scholar
• Frasure-Smith N, Lespérance F. Depression and coronary artery disease. Herz. 2006;31(Suppl 3):64–68.
   PubMed Web of Science ®Google Scholar
• Frasure-Smith N, Lespérance F, Talajic M. Depression following myocardial infarction. Impact on 6-month survival. JAMA. 1993;270:1819–1825.
   PubMed Web of Science ®Google Scholar
• Medvedev VE. Agomelatine in the treatment of mild-to-moderate depression in patients with cardiovascular disease: results of the national multicenter observational study PULSE. Neuropsychiatr Dis Treat. 2017;13:1141–1151.
   PubMed Web of Science ®Google Scholar
• Valdoxan® Product Information. Therapeutic goods administration. Australian Government. Available from: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-07273-3&d=201810151016933&d=201901231016933
   Google Scholar
• Montejo A, Majadas S, Rizvi SJ, et al. The effects of agomelatine on sexual function in depressed patients and healthy volunteers. Hum Psychopharmacol. 2011;26:537–542.
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Rizvi S, Fulton K, et al. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol. 2008;28:329–333.
   PubMed Web of Science ®Google Scholar
• Perlemuter G, Cacoub P, Valla D, et al. Characterisation of agomelatine-induced increase in liver enzymes: frequency and risk factors determined from a pooled analysis of 7605 treated patients. CNS Drugs. 2016;30:877–888.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. CMHP assessment report for valdoxan. [cited 2008 Nov 20]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000915/WC500046226.pdf
   Google Scholar
• Freiesleben SD, Furczyk K. A systematic review of agomelatine-induced liver injury. J Mol Psychiatry. 2015;3:4–12.
   PubMedGoogle Scholar
• Gahr M, Zeiss R, Lang D, et al. Hepatotoxicity associated with agomelatine and other antidepressants: disproportionality analysis using pooled pharmacovigilance data from the Uppsala monitoring centre. J Clin Pharmacol. 2015;55:768–773.
   PubMed Web of Science ®Google Scholar
• De Berardis D, Fornaro M, Serroni N, et al. Agomelatine beyond borders: current evidences of its efficacy in disorders other than major depression. Int J Mol Sci. 2015;16:1111–1130.
   PubMed Web of Science ®Google Scholar
• Norman TR. Agomelatine, melatonin and depressive disorder. Expert Opin Investig Drugs. 2013;22:407–410.
   PubMed Web of Science ®Google Scholar
• Howland RH. Publication bias and outcome reporting bias. Agomelatine as a case example. J Psychosocail Nurs. 2011;49:11–14.
   PubMed Web of Science ®Google Scholar
• Duroux R, Rami M, Landagaray E, et al. Synthesis and biological evaluation of new naphtho- and quinolinocyclopentane derivatives as potent melatoninergic (MT1/MT2) and serotoninergic (5-HT2C) dual ligands. Eur J Med Chem. 2017;141:552–566.
   PubMed Web of Science ®Google Scholar
• Ettaoussi M, Pérès B, Errazani A, et al. Synthesis and pharmacological evaluation of dual ligands for melatonin (MT1/MT2) and serotonin 5-HT2C receptor subtypes (II). Eur J Med Chem. 2015;90:822–833.
   PubMed Web of Science ®Google Scholar